Business Standard

Monday, December 23, 2024 | 05:12 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Covid-19: Gilead drug data lifts hopes, Fauci calls it 'highly significant'

President Donald Trump during a White House meeting greeted Gilead's reports as good news

Healthcare workers take a swab sample of a commuter-train worker during a test amid the coronavirus disease (COVID-19) outbreak, in Bogor, West Java province, Indonesia. Photo: Reuters
Premium

Healthcare workers take a swab sample of a commuter-train worker during a test amid the coronavirus disease (COVID-19) outbreak, in Bogor, West Java province, Indonesia. Photo: Reuters

Deena Beasley and Manas Mishra | Reuters
A top U.S. health official said Gilead Sciences Inc's experimental antiviral drug remdesivir is likely to become the standard of care for COVID-19 after early results from a key clinical trial on Wednesday showed it helped certain patients recover more quickly from the illness caused by the coronavirus.

Preliminary results from a U.S. government trial show that patients given remdesivir had a 31% faster recovery time than those who received a placebo, results hailed by Dr. Anthony Fauci, the nation's top infectious disease expert, as "highly significant."

Gilead earlier on Wednesday said remdesivir helped improve outcomes for patients with COVID-19 in the

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in